European Survey to Gain Insight into Treatment-Experienced Patients' Perspectives on Living with HIV
23/07/2007 06:51
PR Newswire
SYDNEY, Australia, July 23 /PRNewswire/ --
Recent launches of new protease inhibitors and the anticipated
availability of new antiretroviral drug classes have increased the
therapeutic options available to treatment-experienced HIV-positive patients,
and made achieving an undetectable viral load a realistic goal for this
patient population. With these treatment advances, it has become important to
understand the unique needs and perspectives of treatment-experienced
individuals, a growing population.
Coinciding with the annual conference of International AIDS Society (IAS)
in Sydney, Australia, Boehringer Ingelheim announced the launch of the HIV
TALK (Treatment, Attitudes, Life, Knowledge) survey, a project supported by
the International AIDS Society, which will gain insight into
treatment-experienced individuals' attitudes about HIV therapy and living
with HIV, potential gaps in education and information, perceptions toward
treatment and ways to improve patient-physician dialogue about HIV care.
The HIV TALK survey will be fielded to five hundred HIV-positive
individuals who have undergone treatment with multiple antiretrovirals
throughout France, Germany, Italy, Spain and the United Kingdom. These
countries have the largest populations of HIV-positive individuals in Western
Europe.
"Great strides in HIV research enable HIV-positive individuals to live
longer, healthier lives. With these treatment advances, it is also important
to understand treatment-experienced individuals' attitudes, outlooks, and the
level of patient-physician dialogue. Through the HIV TALK survey, we hope to
gain this valuable information and increase awareness of the needs of this
growing patient population and the importance of patient-physician dialogue,"
said Juergen Rockstroh, M.D., professor of medicine, Universitat Bonn,
Germany.(i)
Results are expected in October, 2007. For more information please visit
www.ias.org/media.
Boehringer Ingelheim
Boehringer Ingelheim is a pharmaceutical company committed to the
research and development of novel antiretroviral agents and to improving HIV
therapy by providing physicians and patients with innovative antiretrovirals.
For more information, please see www.boehringer-ingelheim.com/hiv.
About IAS
The IAS is the world's leading independent association of HIV
professionals, with over 10,000 members in 171 countries. The IAS was founded
as a non-profit organisation in connection with the IV International AIDS
Conference in Stockholm in 1988; primarily to decide on future venues of the
series of International AIDS Conferences and to serve as a network for those
working with HIV/AIDS. For more information, please visit
http://www.ias2007.org/media
(i) UNAIDS/WHO: 2006 Report on the global AIDS epidemic
Web site: http://www.boehringer-ingelheim.com/hiv
http://www.iasociety.org/media
Lauren Graham, +1-212-537-8129, for Boehringer Ingelheim